MAPK-related gene signature predicting MAPKi sensitivity in pLGG - Charite cohort

MAPK inhibitor sensitivity scores (MSS) were developed to predict sensitivity to MAPK inhibitors in pediatric low-grade gliomas (pLGG). The scores were validated in pLGG cell lines in vitro and in the publicly available Open Pediatric Brain Tumor Atlas dataset. Validation in independent datasets is warranted. Overall design: Gene expression profiling from primary pLGG samples prior MAPKi therapy